CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo

Experimental Hematology

Volumn 41, Issue 3, 2013, Pages 241-252.e3

  Wang, Yao ^a   Bo, Jian ^a   Dai, Han ren ^a   Lu, Xue chun ^a   Lv, Hai yan ^a   Yang, Bo ^a   Wang, Tao ^a   Han, Wei dong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CYTARABINE; GAMMA INTERFERON; HOMOHARRINGTONINE; INTERLEUKIN 2; MITOXANTRONE; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; AUTOLOGOUS CYTOKINE INDUCED KILLER CELL TRANSFUSION; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKOCYTE COUNT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 84874997536     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.10.014     Document Type: Article

References (35)

1. Estey E., Döhner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
2. Löwenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
3. Litzow M.R., Othus M., Cripe L.D., et al. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematology 2010, 148:217-225.
4. Stone R.M., O'Donnell M.R., Sekeres M.A. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004, 98-117.
5. O'Donnell M.R., Abboud C.N., Altman J., et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2011, 9:280-317.
6. Rubnitz J.E., Gibson B., Smith F.O. Acute myeloid leukemia. Hematol Oncol Clin North Am 2010, 24:35-63.
7. Wongkajornsilp A., Sangsuriyong S., Hongeng S., Waikakul S., Asavamongkolkul A., Huabprasert S. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells. J Ortho Res 2005, 23:1460-1466.
8. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21:1673-1679.
9. Mazumder A., Rosenberg S.A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984, 159:495-507.
10. Edinger M., Cao Y.A., Verneris M.R., Bachmann M.H., Contag C.H., Negrin R.S. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003, 101:640-648.
11. Linn Y.C., Lau L.C., Hui K.M. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002, 116:78-86.
12. Kornacker M., Moldenhauer G., Herbst M., et al. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer 2006, 119:1377-1382.
13. Baker J., Verneris M.R., Ito M., Shizuru J.A., Negrin R.S. Expansion of cytolytic CD8(+) natural killer T cells with limited Capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001, 97:2923-2931.
14. Jiang H., Liu K.Y., Tong C.R., Jiang B., Lu D.P. The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia. Zhonghua Nei Ke Za Zhi 2010, 44:198-201.
15. Lu X.C., Yang B., Yu R.L., et al. Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. Cell Biochem Biophys 2011, 62:257-265.
16. Wang Y., Dai H., Li H., et al. Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol 2011, 621414.
17. Kägi D., Ledermann B., Bürki K., et al. Cytotoxicity mediated by T-cells and natural killer cells is greatly impaired in perforindeficient mice. Nature 1994, 369:31-37.
18. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev 2008, 8:299-308.
19. Bellamy W.T., Richter L., Frutiger Y., Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59:728-733.
20. Lopez R.D., Waller E.K., Lu P.H., Negrin R.S. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother 2001, 49:629-640.
21. Yang B., Lu X.C., Yu R.L., et al. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematol Oncol 2011, 30:115-122.
22. Rosenberg S.A., Lotze M.T., Muul L.M. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985, 313:1485-1492.
23. Mulé J.J., Shu S., Schwarz S.L., Rosenberg S.A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984, 225:1487-1489.
24. Takahashi H., Nakada T., Puisieux I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993, 259:1460-1463.
25. Schmidt-Wolf I.G., Lefterova P., Johnston V., et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996, 169:85-90.
26. + cells from peripheralblood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001, 7:216-222.
27. + cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998, 92:3318-3327.
28. Niam M., Linn Y.C., Fook Chong S., et al. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol 2011, 39:897-903.
29. Karp J.E., Gojo I., Pili R., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-β-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004, 10:3577-3585.
30. Bellamy W.T., Richter L., Sirjani D., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427-1434.
31. Gabrilove J.L., White K., Rahman Z., Wilson E.L. Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth. Blood 1994, 83:907-910.
32. Aguayo A., Estey E., Kantarjian H., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999, 94:3717-3721.
33. Leemhuis T., Wells S., Scheffold C., Edinger M., Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181-187.
34. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
35. Kalos M., Levine B.L., Porter D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.